Company: PRME
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0001193125-25-122156
Chunk: 5

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.02
Chunk 5
---
 be deemed incorporated by reference into this Current Report on Form8-K.

The information in Item 7.01 of this Current Report on Form8-K, including Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, or the Exchange Act, except as expressly set forth by specific reference in such filing.

  Item 8.01      Other Events.  

Appointment of Executive Chair

On May 16, 2025, the Board appointed Jeffrey Marrazzo, a member of the Board, as Executive Chair of the Board, in addition to his service as a director, effective as of May 19, 2025.

Pipeline Prioritization

On May 19, 2025, the Company announced a strategic restructuring, including the deprioritization of its Chronic Granulomatous Disease (“ CGD”) programs, as well as a cost and workforce reduction to focus on its liver franchise and programs funded through external partnerships. The Company will focus its internal efforts on the development of in vivoprograms for the treatment of Wilson’s Disease and Alpha-1Antitrypsin Deficiency (“ AATD”), two of the largest genetic liver diseases. The Company expects to file an investigational new drug (“ IND”) and/or clinical trial application (“ CTA”) for its Wilson’s Disease program in the first half of 2026 and for its AATD program in mid-2026; initial clinical data from both programs are expected in 2027.

The Company will also continue its in vivoCystic Fibrosis program with support from the Cystic Fibrosis Foundation, and its efforts to develop Prime Edited CAR-Tproducts for hematology, immunology and oncology in partnership with Bristol Myers Squibb. The Company is exploring options for the continued clinical development of PM359 external to the Company and ceasing further efforts inX-linkedCGD. The Company believes PM359 has the potential to transform the care of p47phox CGD and is committed to working with urgency to identify an appropriate partner to help ensure this important therapy is delivered to patients. In addition, the Company will continue to pursue additional business development opportunities to accelerate